Cargando…

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra-Peinado, Carla, Grau-Expósito, Judith, Luque-Ballesteros, Laura, Astorga-Gamaza, Antonio, Navarro, Jordi, Gallego-Rodriguez, Jenny, Martin, Mario, Curran, Adrià, Burgos, Joaquin, Ribera, Esteban, Raventós, Berta, Willekens, Rein, Torrella, Ariadna, Planas, Bibiana, Badía, Rosa, Garcia, Felipe, Castellví, Josep, Genescà, Meritxell, Falcó, Vicenç, Buzon, Maria J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697690/
https://www.ncbi.nlm.nih.gov/pubmed/31420544
http://dx.doi.org/10.1038/s41467-019-11556-4
_version_ 1783444413647683584
author Serra-Peinado, Carla
Grau-Expósito, Judith
Luque-Ballesteros, Laura
Astorga-Gamaza, Antonio
Navarro, Jordi
Gallego-Rodriguez, Jenny
Martin, Mario
Curran, Adrià
Burgos, Joaquin
Ribera, Esteban
Raventós, Berta
Willekens, Rein
Torrella, Ariadna
Planas, Bibiana
Badía, Rosa
Garcia, Felipe
Castellví, Josep
Genescà, Meritxell
Falcó, Vicenç
Buzon, Maria J.
author_facet Serra-Peinado, Carla
Grau-Expósito, Judith
Luque-Ballesteros, Laura
Astorga-Gamaza, Antonio
Navarro, Jordi
Gallego-Rodriguez, Jenny
Martin, Mario
Curran, Adrià
Burgos, Joaquin
Ribera, Esteban
Raventós, Berta
Willekens, Rein
Torrella, Ariadna
Planas, Bibiana
Badía, Rosa
Garcia, Felipe
Castellví, Josep
Genescà, Meritxell
Falcó, Vicenç
Buzon, Maria J.
author_sort Serra-Peinado, Carla
collection PubMed
description The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4(+)) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART.
format Online
Article
Text
id pubmed-6697690
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-66976902019-08-19 Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab Serra-Peinado, Carla Grau-Expósito, Judith Luque-Ballesteros, Laura Astorga-Gamaza, Antonio Navarro, Jordi Gallego-Rodriguez, Jenny Martin, Mario Curran, Adrià Burgos, Joaquin Ribera, Esteban Raventós, Berta Willekens, Rein Torrella, Ariadna Planas, Bibiana Badía, Rosa Garcia, Felipe Castellví, Josep Genescà, Meritxell Falcó, Vicenç Buzon, Maria J. Nat Commun Article The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4(+)) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART. Nature Publishing Group UK 2019-08-16 /pmc/articles/PMC6697690/ /pubmed/31420544 http://dx.doi.org/10.1038/s41467-019-11556-4 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Serra-Peinado, Carla
Grau-Expósito, Judith
Luque-Ballesteros, Laura
Astorga-Gamaza, Antonio
Navarro, Jordi
Gallego-Rodriguez, Jenny
Martin, Mario
Curran, Adrià
Burgos, Joaquin
Ribera, Esteban
Raventós, Berta
Willekens, Rein
Torrella, Ariadna
Planas, Bibiana
Badía, Rosa
Garcia, Felipe
Castellví, Josep
Genescà, Meritxell
Falcó, Vicenç
Buzon, Maria J.
Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
title Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
title_full Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
title_fullStr Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
title_full_unstemmed Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
title_short Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
title_sort expression of cd20 after viral reactivation renders hiv-reservoir cells susceptible to rituximab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697690/
https://www.ncbi.nlm.nih.gov/pubmed/31420544
http://dx.doi.org/10.1038/s41467-019-11556-4
work_keys_str_mv AT serrapeinadocarla expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT grauexpositojudith expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT luqueballesteroslaura expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT astorgagamazaantonio expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT navarrojordi expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT gallegorodriguezjenny expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT martinmario expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT curranadria expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT burgosjoaquin expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT riberaesteban expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT raventosberta expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT willekensrein expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT torrellaariadna expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT planasbibiana expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT badiarosa expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT garciafelipe expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT castellvijosep expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT genescameritxell expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT falcovicenc expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab
AT buzonmariaj expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab